Development of T-cell engagers selective for cells co-expressing two antigens

Development of T-cell engagers selective for cells co-expressing two antigens

T cell-engaging bispecific antibodies (TCEs) are clinically effective treatments for hematological cancers. While the utility of TCEs in solid malignancies is being explored, toxicities arising from antigen expression on normal tissues have slowed or halted several clinical trials. Here, we describe...

Full description

Bibliographic Details
Main Authors: Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson, Nicholas J. Agard
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:mAbs
Subjects:
T-cell engagers
multivalent antibodies
cancer
antibody engineering
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2022.2115213

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2022.2115213

Similar Items